JP2019529402A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529402A5
JP2019529402A5 JP2019513787A JP2019513787A JP2019529402A5 JP 2019529402 A5 JP2019529402 A5 JP 2019529402A5 JP 2019513787 A JP2019513787 A JP 2019513787A JP 2019513787 A JP2019513787 A JP 2019513787A JP 2019529402 A5 JP2019529402 A5 JP 2019529402A5
Authority
JP
Japan
Prior art keywords
compound
composition
group
use according
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019513787A
Other languages
English (en)
Japanese (ja)
Other versions
JP7046381B2 (ja
JP2019529402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073747 external-priority patent/WO2018054959A1/en
Publication of JP2019529402A publication Critical patent/JP2019529402A/ja
Publication of JP2019529402A5 publication Critical patent/JP2019529402A5/ja
Application granted granted Critical
Publication of JP7046381B2 publication Critical patent/JP7046381B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019513787A 2016-09-20 2017-09-20 リポタンパク質代謝障害の治療のための化合物 Expired - Fee Related JP7046381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670733 2016-09-20
DKPA201670733 2016-09-20
PCT/EP2017/073747 WO2018054959A1 (en) 2016-09-20 2017-09-20 Compounds for treatment of lipoprotein metabolism disorders

Publications (3)

Publication Number Publication Date
JP2019529402A JP2019529402A (ja) 2019-10-17
JP2019529402A5 true JP2019529402A5 (enExample) 2020-11-05
JP7046381B2 JP7046381B2 (ja) 2022-04-04

Family

ID=59974406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513787A Expired - Fee Related JP7046381B2 (ja) 2016-09-20 2017-09-20 リポタンパク質代謝障害の治療のための化合物

Country Status (9)

Country Link
US (2) US11173177B2 (enExample)
EP (1) EP3515455B1 (enExample)
JP (1) JP7046381B2 (enExample)
CN (1) CN110494145A (enExample)
AU (1) AU2017329799A1 (enExample)
CA (1) CA3035875A1 (enExample)
DK (1) DK3515455T3 (enExample)
ES (1) ES2871783T3 (enExample)
WO (1) WO2018054959A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170123345A (ko) * 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
KR102137147B1 (ko) * 2018-07-16 2020-07-24 경희대학교 산학협력단 벤질 알파-d-갈락토피라노사이드 또는 (-)-세코이소라리시레시놀-9'-o-베타-d-글루코피라노사이드를 포함하는 당뇨병 예방 또는 치료용 조성물
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
WO2021122793A1 (en) * 2019-12-17 2021-06-24 Norinvent Ab Sulfated disaccharides as enhancers of transmucosal drug uptake
IL300439A (en) 2020-08-25 2023-04-01 Regeneron Pharma Treatment of sepsis with PCSK9 and LDLR modulators
CN116854752A (zh) * 2022-03-28 2023-10-10 南开大学 肝素三糖结构化合物及其制药应用
CN116270507A (zh) * 2023-03-02 2023-06-23 青岛海洋生物医药研究院股份有限公司 一种含脂蛋白脂酶刺激剂的舌下含片及其制备方法和应用
CN119708089A (zh) * 2023-09-27 2025-03-28 南开大学 一种磺酸化三糖及其制备方法和治疗应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
WO1993007167A1 (en) * 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5366473A (en) 1992-08-18 1994-11-22 Ultrasonic Sensing And Monitoring Systems, Inc. Method and apparatus for applying vascular grafts
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
DE69327229T2 (de) 1992-12-11 2000-03-30 The Dow Chemical Co., Midland Multivalente einkettige Antikörper
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2008314505C1 (en) * 2007-10-16 2020-11-05 Progen Pg500 Series Pty Ltd Novel sulfated oligosaccharide derivatives
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
KR101293278B1 (ko) 2009-10-29 2013-08-09 주식회사 한독 신규 혈관누출 차단제
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013177536A2 (en) 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA2877766A1 (en) 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
EP2970501A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
KR20170123345A (ko) * 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제

Similar Documents

Publication Publication Date Title
JP2019529402A5 (enExample)
JP2020531418A5 (enExample)
JP2019535672A5 (enExample)
JP2021500403A5 (enExample)
JP2009530399A5 (enExample)
JP2008520742A5 (enExample)
JP2007502264A5 (enExample)
JP2019531279A5 (enExample)
JP2024167182A5 (enExample)
JP2011520815A5 (enExample)
JP2015051994A5 (enExample)
JP2016534148A5 (enExample)
JP2012504133A5 (enExample)
JP2013520502A5 (enExample)
JP2019510039A5 (enExample)
JP2010511626A5 (enExample)
JP2005506348A5 (enExample)
JP2010077141A5 (enExample)
JP2009529540A5 (enExample)
JP2018135343A5 (enExample)
JP2016531126A5 (enExample)
JP2010540556A5 (enExample)
JP2003306481A5 (enExample)
JP2015508092A5 (enExample)
JP2018538273A5 (enExample)